Name | Number of supported studies | Average coverage | |
---|---|---|---|
endothelial cell | 9 studies | 27% ± 7% | |
classical monocyte | 8 studies | 24% ± 10% | |
oligodendrocyte | 7 studies | 27% ± 7% | |
glutamatergic neuron | 6 studies | 43% ± 25% | |
epithelial cell | 6 studies | 33% ± 12% | |
basal cell | 6 studies | 26% ± 10% | |
adipocyte | 6 studies | 21% ± 4% | |
GABAergic neuron | 6 studies | 36% ± 19% | |
astrocyte | 6 studies | 30% ± 11% | |
oligodendrocyte precursor cell | 6 studies | 30% ± 12% | |
microglial cell | 5 studies | 20% ± 5% | |
erythrocyte | 5 studies | 30% ± 13% | |
natural killer cell | 4 studies | 19% ± 1% | |
B cell | 4 studies | 19% ± 3% | |
CD16-positive, CD56-dim natural killer cell, human | 4 studies | 17% ± 1% | |
fibroblast | 4 studies | 27% ± 8% | |
ciliated cell | 4 studies | 25% ± 5% | |
macrophage | 4 studies | 20% ± 5% | |
interneuron | 4 studies | 40% ± 22% | |
secretory cell | 3 studies | 22% ± 9% | |
non-classical monocyte | 3 studies | 29% ± 8% | |
neuron | 3 studies | 32% ± 11% | |
retinal bipolar neuron | 3 studies | 26% ± 5% | |
amacrine cell | 3 studies | 29% ± 10% | |
retina horizontal cell | 3 studies | 23% ± 5% | |
retinal cone cell | 3 studies | 31% ± 11% | |
rod bipolar cell | 3 studies | 19% ± 4% | |
type I pneumocyte | 3 studies | 18% ± 2% | |
type II pneumocyte | 3 studies | 26% ± 8% | |
abnormal cell | 3 studies | 22% ± 9% | |
monocyte | 3 studies | 18% ± 3% | |
pericyte | 3 studies | 19% ± 4% | |
transit amplifying cell | 3 studies | 26% ± 13% | |
CD8-positive, alpha-beta memory T cell | 3 studies | 18% ± 2% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
esophagus | 100% | 5595.20 | 1445 / 1445 | 100% | 19.45 | 183 / 183 |
pancreas | 100% | 3831.78 | 328 / 328 | 100% | 15.08 | 178 / 178 |
breast | 100% | 4567.20 | 459 / 459 | 100% | 26.26 | 1117 / 1118 |
intestine | 100% | 4742.38 | 966 / 966 | 100% | 15.06 | 526 / 527 |
prostate | 100% | 4701.38 | 245 / 245 | 100% | 25.76 | 501 / 502 |
stomach | 100% | 4529.07 | 359 / 359 | 100% | 14.62 | 285 / 286 |
bladder | 100% | 4092.38 | 21 / 21 | 100% | 16.06 | 502 / 504 |
uterus | 100% | 4536.72 | 170 / 170 | 100% | 17.93 | 457 / 459 |
thymus | 100% | 4938.18 | 653 / 653 | 100% | 20.70 | 602 / 605 |
lung | 100% | 3842.54 | 576 / 578 | 100% | 20.38 | 1153 / 1155 |
brain | 99% | 4219.85 | 2624 / 2642 | 100% | 22.64 | 705 / 705 |
ovary | 100% | 3937.81 | 180 / 180 | 99% | 14.43 | 426 / 430 |
liver | 100% | 3676.06 | 226 / 226 | 99% | 16.81 | 400 / 406 |
kidney | 100% | 4064.54 | 89 / 89 | 98% | 16.21 | 885 / 901 |
adrenal gland | 100% | 13025.93 | 258 / 258 | 98% | 21.55 | 225 / 230 |
skin | 100% | 3754.27 | 1809 / 1809 | 97% | 21.26 | 460 / 472 |
adipose | 100% | 4071.12 | 1204 / 1204 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 100% | 14.86 | 29 / 29 |
spleen | 100% | 4747.00 | 241 / 241 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 100% | 17.33 | 45 / 45 |
blood vessel | 100% | 4464.70 | 1334 / 1335 | 0% | 0 | 0 / 0 |
muscle | 100% | 2498.52 | 802 / 803 | 0% | 0 | 0 / 0 |
peripheral blood | 99% | 3835.73 | 923 / 929 | 0% | 0 | 0 / 0 |
heart | 97% | 2532.49 | 831 / 861 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 90% | 14.04 | 72 / 80 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
GO_0016567 | Biological process | protein ubiquitination |
GO_0031146 | Biological process | SCF-dependent proteasomal ubiquitin-dependent protein catabolic process |
GO_0070936 | Biological process | protein K48-linked ubiquitination |
GO_0032006 | Biological process | regulation of TOR signaling |
GO_0043161 | Biological process | proteasome-mediated ubiquitin-dependent protein catabolic process |
GO_0045444 | Biological process | fat cell differentiation |
GO_0045087 | Biological process | innate immune response |
GO_0019005 | Cellular component | SCF ubiquitin ligase complex |
GO_0000151 | Cellular component | ubiquitin ligase complex |
GO_0005829 | Cellular component | cytosol |
GO_0005737 | Cellular component | cytoplasm |
GO_1990756 | Molecular function | ubiquitin-like ligase-substrate adaptor activity |
GO_0004842 | Molecular function | ubiquitin-protein transferase activity |
GO_0005515 | Molecular function | protein binding |
Gene name | FBXO9 |
Protein name | F-box protein 9 F-box only protein F-box only protein 9 (Cross-immune reaction antigen 1) (Renal carcinoma antigen NY-REN-57) |
Synonyms | FBX9 VCIA1 |
Description | FUNCTION: Substrate recognition component of a SCF (SKP1-CUL1-F-box protein) E3 ubiquitin-protein ligase complex which mediates the ubiquitination and subsequent proteasomal degradation of target proteins and plays a role in several biological processes such as cell cycle, cell proliferation, or maintenance of chromosome stability . Ubiquitinates mTORC1-bound TTI1 and TELO2 when they are phosphorylated by CK2 following growth factor deprivation, leading to their degradation. In contrast, does not mediate ubiquitination of TTI1 and TELO2 when they are part of the mTORC2 complex. As a consequence, mTORC1 is inactivated to restrain cell growth and protein translation, while mTORC2 is the activated due to the relief of feedback inhibition by mTORC1 . Plays a role in maintaining epithelial cell survival by regulating the turn-over of chromatin modulator PRMT4 through ubiquitination and degradation by the proteasomal pathway . Regulates also PPARgamma stability by facilitating PPARgamma/PPARG ubiquitination and thereby plays a role in adipocyte differentiation (By similarity). . FUNCTION: Substrate recognition component of a SCF (SKP1-CUL1-F-box protein) E3 ubiquitin-protein ligase complex which mediates the ubiquitination and subsequent proteasomal degradation of target proteins and plays a role in several biological processes such as cell cycle, cell proliferation, or maintenance of chromosome stability. Ubiquitinates mTORC1-bound TTI1 and TELO2 when they are phosphorylated by CK2 following growth factor deprivation, leading to their degradation. In contrast, does not mediate ubiquitination of TTI1 and TELO2 when they are part of the mTORC2 complex. As a consequence, mTORC1 is inactivated to restrain cell growth and protein translation, while mTORC2 is the activated due to the relief of feedback inhibition by mTORC1. Plays a role in maintaining epithelial cell survival by regulating the turn-over of chromatin modulator PRMT4 through ubiquitination and degradation by the proteasomal pathway. Regulates also PPARgamma stability by facilitating PPARgamma/PPARG ubiquitination and thereby plays a role in adipocyte differentiation. . |
Accessions | C9IY65 V9GZ74 ENST00000473318.1 ENST00000473337.6 ENST00000323557.12 [Q9UK97-2] ENST00000244426.10 [Q9UK97-1] C9J4V1 ENST00000459845.6 ENST00000370939.7 [Q9UK97-3] Q9UK97 ENST00000498744.5 C9JDZ9 H7C4H6 ENST00000484436.7 |